IL237730B - Treatment of mild and moderate Alzheimer's disease - Google Patents

Treatment of mild and moderate Alzheimer's disease

Info

Publication number
IL237730B
IL237730B IL237730A IL23773015A IL237730B IL 237730 B IL237730 B IL 237730B IL 237730 A IL237730 A IL 237730A IL 23773015 A IL23773015 A IL 23773015A IL 237730 B IL237730 B IL 237730B
Authority
IL
Israel
Prior art keywords
mild
disease
treatment
moderate alzheimer
alzheimer
Prior art date
Application number
IL237730A
Other languages
English (en)
Hebrew (he)
Original Assignee
Vtv Therapeutics Llc
Vtvx Holdings I Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc, Vtvx Holdings I Llc filed Critical Vtv Therapeutics Llc
Publication of IL237730B publication Critical patent/IL237730B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
IL237730A 2012-10-05 2015-03-12 Treatment of mild and moderate Alzheimer's disease IL237730B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261710229P 2012-10-05 2012-10-05
PCT/US2013/062964 WO2014055588A1 (en) 2012-10-05 2013-10-02 Treatment of mild and moderate alzheimer's disease

Publications (1)

Publication Number Publication Date
IL237730B true IL237730B (en) 2018-10-31

Family

ID=49354960

Family Applications (1)

Application Number Title Priority Date Filing Date
IL237730A IL237730B (en) 2012-10-05 2015-03-12 Treatment of mild and moderate Alzheimer's disease

Country Status (15)

Country Link
EP (1) EP2903606A1 (enExample)
JP (2) JP6566868B2 (enExample)
KR (1) KR20150064743A (enExample)
CN (2) CN110292638A (enExample)
AU (2) AU2013327450B2 (enExample)
BR (1) BR112015007641A8 (enExample)
CA (1) CA2886785C (enExample)
EA (1) EA201590687A1 (enExample)
HK (1) HK1207004A1 (enExample)
IL (1) IL237730B (enExample)
IN (1) IN2015DN03734A (enExample)
MX (1) MX377733B (enExample)
NZ (2) NZ739521A (enExample)
SG (2) SG10201702648YA (enExample)
WO (1) WO2014055588A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) * 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
EP3864008A1 (en) 2018-10-10 2021-08-18 vTv Therapeutics LLC Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
WO2020086388A1 (en) * 2018-10-22 2020-04-30 Vtv Therapeutics Llc Glucokinase activator compositions for the treatment of cognitive impairment
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
CN114716551B (zh) * 2021-11-12 2023-01-24 深圳市人民医院 靶向rage的纳米抗体及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613321A (zh) * 2002-03-05 2009-12-30 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
EP1707203A1 (en) * 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
JP2010523559A (ja) * 2007-04-05 2010-07-15 トランス テック ファーマ,インコーポレイテッド [3−(4−{2−ブチル−1−[4−(4−クロロ−フェノキシ)−フェニル]−1h−イミダゾール−4−イル}−フェノキシ)−プロピル]−ジエチルアミンの結晶形態
CN101663280A (zh) * 2007-04-05 2010-03-03 转化技术制药公司 [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
US20090221554A1 (en) * 2008-02-28 2009-09-03 Zenyaku Kogyo Kabushiki Kaisha Method of treating cognitive impairment
EP2638052B1 (en) * 2010-11-08 2017-03-22 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof

Also Published As

Publication number Publication date
JP6566868B2 (ja) 2019-08-28
AU2013327450B2 (en) 2018-07-12
SG10201702648YA (en) 2017-04-27
AU2013327450A1 (en) 2015-05-14
MX377733B (es) 2025-03-11
CN104703592A (zh) 2015-06-10
NZ739521A (en) 2019-06-28
CA2886785A1 (en) 2014-04-10
KR20150064743A (ko) 2015-06-11
SG11201502210VA (en) 2015-04-29
WO2014055588A1 (en) 2014-04-10
CA2886785C (en) 2022-06-07
CN110292638A (zh) 2019-10-01
NZ705813A (en) 2018-02-23
JP2019163301A (ja) 2019-09-26
IN2015DN03734A (enExample) 2015-09-18
BR112015007641A8 (pt) 2018-04-03
HK1207004A1 (zh) 2016-01-22
EP2903606A1 (en) 2015-08-12
MX2015003732A (es) 2015-09-23
JP2015535850A (ja) 2015-12-17
EA201590687A1 (ru) 2015-09-30
BR112015007641A2 (pt) 2017-07-04
JP6894940B2 (ja) 2021-06-30
AU2018203434A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
IL237369A0 (en) Methods for treating Alzheimer's disease and pharmaceutical compositions thereof
IL265774B (en) Diagnosis, prevention and treatment of joint diseases
HUE041553T2 (hu) Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
EP2890440A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES
EP3261721A4 (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
EP2707369A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
IL225239A0 (en) Compounds for the treatment of acne and related diseases
ZA201500561B (en) Compositions and treatment for eye diseases and disorders
ZA201408055B (en) Compositions and methods for the treatment of local pain
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
EP2568811A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
HUS2000020I1 (hu) Ciklezonid a légúti betegségek kezelésére lovaknál
IL260078B (en) Therapy used to treat Gaucher disease
IL237730B (en) Treatment of mild and moderate Alzheimer's disease
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
IL233572B (en) A pharmaceutical preparation containing a mixture with fixed doses for the treatment of Parkinson's disease
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
AP2014007905A0 (en) Novel compounds for the treatment of dyslipidemia and related diseases
ZA201408057B (en) Compositions and methods for the treatment of moderate to severe pain
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
EP2934501A4 (en) USES AND METHOD FOR THE TREATMENT OF LIVER DISEASES OR DRESSES
PL2565184T3 (pl) Środek terapeutyczny i środek zapobiegawczy przeciwko chorobie alzheimera
HK1183408A (en) Treatment of mci and alzheimer's disease

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed